Regulations and Regulatory Advocacy
The AHA and Federation of American Hospitals Aug. 8 filed an amicus brief in the U.S. District Court for the Eastern District of Texas in support of the U.S. Chamber of Commerce’s lawsuit against the Federal Trade Commission, explaining that changes made by the FTC to premerger notification rules…
President Trump Aug. 7 issued an executive order, “Improving Oversight of Federal Grantmaking,” requiring government agencies to review new and discretionary grants to ensure grant funding advances the administration’s policy priorities.
The Centers for Medicare & Medicaid Services (CMS) June 30 issued its proposed rule for the calendar year (CY) 2026 home health (HH) prospective payment system (PPS). Comments are due Sept. 2, and a final rule is expected around Nov. 1. New policies would generally be effective Jan. 1, 2026.
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system rates by a net 2.4% in calendar year 2026 compared to 2025.
AHA comments on the U.S. Department of Health and Human Services request for information to ensure lawful regulation and unleash innovation to promote better health.
The AHA provides an overview of the key statutes and regulations that have impeded competition in the health care market and offer a series of recommendations to remedy these obstacles.
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies’ requests for information on unnecessary or burdensome anticompetitive regulations.
The AHA provides an overview of the key statutes and regulations that have impeded competition in the health care market and offer a series of recommendations to remedy these obstacles.
The Department of Health and Human Services May 13 announced (https://www.hhs.gov/press-room/fda-10-to-1-deregulatory-plan-to-lower-costs-empower-patients.html) a 60-day public comment period opened for stakeholders regarding its request for information (https://public-inspection.federalregister.…
Directs the Commissioner of the Food and Drug Administration to review and eliminate any duplicative or unnecessary requirements in regulations and guidance pertaining to the development of domestic pharmaceutical manufacturing within 180 days.